India Market Growth and Financial Performance
North America: Delivering on Complex Generics
Leadership: 4.3% TRX
volume share in U.S.1
Growing Respiratory
portfolio
LUPIN
Consistent ramp up in sales
DE
US Sales ($mn)
177
175
181
213 212
#3
#1
22.5%
Albuterol
in the US¹
in 50 products²
Q3
Q4
Q1
Q2
Maintaining
leadership
Top 3 in 102
products²
FY23
FY23
FY24
FY24
Q3
FY24
market share
In generics¹
20% YoY
flat QoQ
Q3 FY24 Key Highlights
Focus on profitable growth
Share of inhalation portfolio at ~40% of sales
Legacy products maintaining market share
●
•
28.6%
Arfomoterol
market share
Brand + generic¹
Continued momentum led by investments in complex
Gx, 505(b)(2) and biosimilars
Upscaling portfolio to higher share of complex Gx, led
by inhalation, injectables and biosimilars
Strong pipeline 40+ Injectables and 20+ inhalation
●
51 FTFs incl. 18 exclusive FTFs
Note:
1.
IQVIA Qtr TRX Dec-23 by prescriptions
Continued cost optimization initiatives to improve profitability
2.
IQVIA Qtr Dec-23 NSP data
9View entire presentation